FDA posts briefing docs for Merck's grass allergy product

FDA reviewers provided a summary of the efficacy and safety data for Grastek grass Allergy Immunotherapy Tablet (AIT) ( MK-7243) from Merck & Co. Inc. (NYSE:MRK), but the reviewers did not take a position on approval of the product. Merck is seeking approval of Grastek to treat Timothy grass pollen induced allergic rhinitis, with or without conjunctivitis, in individuals five years of age and older. The summary came in ALK-Abello A/S (CSE:ALK-B), which markets the product as Grazax in Europe. ALK-Abello was up DKK19 to DKK607 on Tuesday. ...